68761-98-8

Basic information

• Product Name: H-Ser(OBn)-OH trifluoroacetate
• Synonyms: H-Ser(OBn)-OH trifluoroacetate
• CAS NO: 68761-98-8
• Molecular Weight: 309.242
• Mol File: 68761-98-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: H-Ser(OBn)-OH trifluoroacetate(CAS DataBase Reference)
• NIST Chemistry Reference: H-Ser(OBn)-OH trifluoroacetate(68761-98-8)
• EPA Substance Registry System: H-Ser(OBn)-OH trifluoroacetate(68761-98-8)

Safety Data

• Hazardous Substances Data: 68761-98-8(Hazardous Substances Data)

Upstream product

• 20806-43-3 Z-Ser(Bzl)-OH 
• 76-05-1 trifluoroacetic acid 
• 23680-31-1 BOC-O-benzyl-L-serine 

Downstream Products

• 130111-08-9 (S)-3-(benzyloxy)-2-hydroxypropanoic acid 

Relevant articles and documents

MgI2-Mediated Chemoselective Cleavage of Protecting Groups: An Alternative to Conventional Deprotection Methodologies

The scope of MgI2 as a valuable tool for quantitative and mild chemoselective cleavage of protecting groups is described here. This novel synthetic approach expands the use of protecting groups, widens the concept of orthogonality in synthetic processes, and offers a facile opportunity to release compounds from solid supports. Amazing MgI2: Protecting groups have had a tremendous positive impact on the art of biomolecule synthesis. In a context in which the use of attractive protecting groups is often limited by harsh deprotection conditions and low chemoselective flexibility, MgI2 offers, by the execution of a very simple protocol, a fresh vision with extensive perspectives.

PEPTIDOMIMETICS SELECTIVE FOR THE SOMATOSTATIN RECEPTOR SUBTYPES 1 AND/OR 4

The invention relates to (hetero)arylsulfonylamino based peptidomimetics of formula (I), wherein A, D, E, J, Q1 R1 , R2, R3, p and j are defined as disclosed, or a pharmaceutically acceptable salt or ester thereof. Compounds of formula (I) possess high affinity and selectivity for the somatostatin receptor subtypes sst1 and/or sst4 and can be used for the treatment or diagnosis of diseases or conditions wherein sst1 and/or sst4 agonists or antagonists are indicated to be useful.